EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Xiaoming Liu, Xuejiao Zeng, Jinli Mahe, Kai Guo, Panpan He, Qianwen Yang, Zhiwei Zhang, Zhongxia Li, Di Wang, Zheqing Zhang, Lei Wang, Lipeng Jing iD

Nutrients · 2023

DOI: 10.3390/nu15194239 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Xiaoming Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Monascus, Hypercholesterolemia, Dyslipidemias, Hyperlipidemias. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BYHEALTH, the Fundamental Research Funds for the Central Universities, the Gansu Province Science Foundation for Youths.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of −0.52 (95% CI: −0.51 to −0.54) mmol/L, −0.43 (95% CI: −0.45 to −0.41) mmol/L, −0.52 (95% CI: −0.52 to −0.52) mmol/L, and −0.29 (95% CI: −0.30 to −0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonascusHypercholesterolemiaDyslipidemiasHyperlipidemiasHumansCholesterol, LDLCholesterol, HDLCarotid Intima-Media ThicknessTriglyceridesDouble-Blind MethodSubtilisins

Stichwörter der Autor:innen

dyslipidemialovastatinnattokinasenattokinase-monascus supplementsred yeast rice

Substanzen

Cholesterol, LDLCholesterol, HDLTriglyceridesnattokinaseSubtilisins

Autor:innen und Institutionen

  • Institute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
  • BYHEALTH Institute of Nutrition & Health, No.3 Kehui 3rd Street, No.99 Kexue Avenue Central, Huangpu District, Guangzhou 510663, China.
  • Department of Nutrition and Food Hygiene, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
  • Department of Neurology, Lanzhou University Second Hospital, Lanzhou 730030, China.

ORCID-Profile: Lipeng Jing

Förderung

  • BYHEALTH
  • the Fundamental Research Funds for the Central Universities
  • the Gansu Province Science Foundation for Youths

Zitieren

APA

Liu, X., Zeng, X., Mahe, J., Guo, K., He, P., Yang, Q., Zhang, Z., Li, Z., Wang, D., Zhang, Z., Wang, L., & Jing, L. (2023). The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. https://doi.org/10.3390/nu15194239

Vancouver

Liu X, Zeng X, Mahe J, Guo K, He P, Yang Q, et al. The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2023. doi:10.3390/nu15194239

BibTeX
@article{Liu2023,
  author = {Liu, Xiaoming and Zeng, Xuejiao and Mahe, Jinli and Guo, Kai and He, Panpan and Yang, Qianwen and Zhang, Zhiwei and Li, Zhongxia and Wang, Di and Zhang, Zheqing and Wang, Lei and Jing, Lipeng},
  title = {The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15194239}
}
Kostenlos starten →